February 26, 2014European Journal of Cardio-Thoracic Surgery
Single-centre experience with next-generation devices for transapical aortic valve implantation†
Key result
Next-generation transapical TAVI achieves ~97% procedural success in high-risk patients.
- n=200
Why the study?
Does transapical TAVI with next-generation devices improve short-term outcomes in high surgical risk patients with aortic stenosis?
Population
200 consecutive patients with aortic stenosis at high surgical risk, mean age 80.5±6.7 years, 38.5% female…
Design
Cohort
Follow-up
median 219 days
Authors
Discussion
Loading...
Member takes
Implication
May support next-generation transapical TAVI in selected high-risk patients; extends observational data but leaves open randomized confirmation.
Study Design
Type
Cohort (n=200)
Multicenter
No
Structured PICO
Does transapical TAVI with next-generation devices improve short-term outcomes in high surgical risk patients with aortic stenosis?
P
Population
200 consecutive patients (mean age 80.5 years, 38.5% female) with aortic stenosis at high surgical risk undergoing transapical TAVI, followed for a median of 219 days.
E
Exposure
Transapical transcatheter aortic valve implantation (TAVI) with next-generation transcatheter heart valves (Engager n=50, JenaValve n=88, Symetis Acurate n=62).
O
Outcome
Short-term outcomes assessed according to standardized Valve Academic Research Consortium (VARC) end points.
Next-generation transapical TAVI devices demonstrate high procedural success, positive hemodynamic results, and low rates of relevant paravalvular regurgitation in high-risk patients with aortic stenosis.
Limitations
- Long-term follow-up is required to investigate the durability of these new devices.
- Long-term follow-up is required to investigate the durability of these new devices
Cite This Study
Seiffert et al. (2014) conducted a cohort in aortic stenosis (n=200). Transapical TAVI with next-generation THV was evaluated on Successful implantation. Transapical TAVI with next-generation devices in high-risk patients achieved a 96.5% procedural success rate, with 30-day and 1-year overall survival rates of 91.5% and 73.9%, respectively.